Genyro licensed Sidewinder, a DNA assembly technology from Caltech, to build complex, high‑accuracy DNA sequences at scale for synthetic biology applications. The platform published in Nature reportedly achieves long‑sequence assembly with a one‑in‑1,000,000 misconnection rate—orders of magnitude better than prior standards—reducing the need for clonal screening. Genyro plans to pair AI‑driven genome design with Sidewinder’s assembly to accelerate programmable biology across therapeutics, industrial biotech and materials. The company emphasized built‑in pathogenicity screening and governance controls as part of its commercialization approach.